Among trial finishers, omalizumab and oral immunotherapy offered similar protection against food allergies, and some people ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

A new study looked at a medicine called omalizumab, usually used for asthma, to see if it could help these kids. Researchers found that this drug helped many children eat foods they were allergic to.

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...

Omalizumab works by binding to the antibodies that promote allergic reactions, rendering them inactive, researchers said in background notes. The drug has been on the market since 2003 ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...